San Francisco startup Structure Therapeutics can be working on an oral, when-everyday GLP-1 drug called GSBR-1290—the drug surpassed Wall Road’s expectations in June any time a mid-phase research showed average weight loss of all over 6% and it programs to start A further mid-phase trial in the direction of the tip of this yr—that founder and